CN103501790B - 用于神经轴突的髓鞘再生的6-取代的雌二醇衍生物 - Google Patents

用于神经轴突的髓鞘再生的6-取代的雌二醇衍生物 Download PDF

Info

Publication number
CN103501790B
CN103501790B CN201280014512.2A CN201280014512A CN103501790B CN 103501790 B CN103501790 B CN 103501790B CN 201280014512 A CN201280014512 A CN 201280014512A CN 103501790 B CN103501790 B CN 103501790B
Authority
CN
China
Prior art keywords
methyl
phenanthrene
diol
decahydro
cyclopenta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280014512.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103501790A (zh
Inventor
J·G·雅格尔
S·奈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endece LLC
Original Assignee
Endece LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endece LLC filed Critical Endece LLC
Priority to CN201610455383.0A priority Critical patent/CN106420767A/zh
Publication of CN103501790A publication Critical patent/CN103501790A/zh
Application granted granted Critical
Publication of CN103501790B publication Critical patent/CN103501790B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201280014512.2A 2011-03-21 2012-03-21 用于神经轴突的髓鞘再生的6-取代的雌二醇衍生物 Expired - Fee Related CN103501790B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610455383.0A CN106420767A (zh) 2011-03-21 2012-03-21 用于神经轴突的髓鞘再生的6‑取代的雌二醇衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161454873P 2011-03-21 2011-03-21
US61/454,873 2011-03-21
PCT/US2012/029973 WO2012129324A2 (en) 2011-03-21 2012-03-21 6-substituted estradiol derivatives for use in remyelination of nerve axons

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610455383.0A Division CN106420767A (zh) 2011-03-21 2012-03-21 用于神经轴突的髓鞘再生的6‑取代的雌二醇衍生物

Publications (2)

Publication Number Publication Date
CN103501790A CN103501790A (zh) 2014-01-08
CN103501790B true CN103501790B (zh) 2016-08-17

Family

ID=46877849

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280014512.2A Expired - Fee Related CN103501790B (zh) 2011-03-21 2012-03-21 用于神经轴突的髓鞘再生的6-取代的雌二醇衍生物
CN201610455383.0A Pending CN106420767A (zh) 2011-03-21 2012-03-21 用于神经轴突的髓鞘再生的6‑取代的雌二醇衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610455383.0A Pending CN106420767A (zh) 2011-03-21 2012-03-21 用于神经轴突的髓鞘再生的6‑取代的雌二醇衍生物

Country Status (13)

Country Link
US (2) US9364486B2 (cg-RX-API-DMAC7.html)
EP (1) EP2688570B1 (cg-RX-API-DMAC7.html)
JP (1) JP6174563B2 (cg-RX-API-DMAC7.html)
KR (1) KR102080151B1 (cg-RX-API-DMAC7.html)
CN (2) CN103501790B (cg-RX-API-DMAC7.html)
AU (1) AU2012230974B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013024168A2 (cg-RX-API-DMAC7.html)
CA (1) CA2830515C (cg-RX-API-DMAC7.html)
DK (1) DK2688570T3 (cg-RX-API-DMAC7.html)
ES (1) ES2561536T3 (cg-RX-API-DMAC7.html)
MX (1) MX354409B (cg-RX-API-DMAC7.html)
SG (1) SG193380A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012129324A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129324A2 (en) * 2011-03-21 2012-09-27 Endece Llc 6-substituted estradiol derivatives for use in remyelination of nerve axons
WO2014064712A2 (en) * 2012-10-22 2014-05-01 Intas Pharmaceuticals Limited An improved process for the preparation of fulvestrant
JP2017512769A (ja) * 2014-03-19 2017-05-25 エンディース エルエルシーＥｎｄｅｃｅ，Ｌｌｃ アルツハイマー病の治療のための６−置換エストラジオール誘導体
US20210024568A1 (en) * 2019-07-23 2021-01-28 Endece Llc Methods for modulation of lipoprotein lipase and apolipoprotein c2 expression and/or activity in the treatment of peripheral and central nervous system tissue disease states

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136160A (en) * 1977-08-17 1979-01-23 Cohen Steven R Specific assay for active demyelinization
JPH0193529A (ja) * 1987-10-05 1989-04-12 Mect Corp シアロシルコレステロールの脱髄性疾患治療剤
JPH01193529A (ja) 1988-01-27 1989-08-03 Yoshitsugu Takano 液体循環装置
US8168621B2 (en) * 2005-09-30 2012-05-01 Endece, Llc 6-substituted estradiol derivatives and methods of use
JP5255444B2 (ja) * 2005-09-30 2013-08-07 エンディース エルエルシー （ｓ）−６−メチルオキサアルキルエキセメスタン化合物および関連する使用方法
US10174070B2 (en) 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
KR101499266B1 (ko) * 2006-11-30 2015-03-05 엔디씨, 엘엘씨 6-알콕시알킬 에스트라디올 유도체 및 사용법
AU2011302065B2 (en) 2010-09-14 2016-12-01 Endece, Llc 6-substituted demethyl-estradiol derivatives as ER-beta agonists
WO2012129324A2 (en) * 2011-03-21 2012-09-27 Endece Llc 6-substituted estradiol derivatives for use in remyelination of nerve axons

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Oestrogen receptor ligand: a novel treatment to enhance endogenous functional remyelination;D.K.CRAWFORD等;《BRAIN》;20100921;第133卷(第10期);2999-3016 *

Also Published As

Publication number Publication date
AU2012230974A1 (en) 2013-09-26
US9636348B2 (en) 2017-05-02
CA2830515C (en) 2015-09-15
EP2688570A4 (en) 2014-09-10
BR112013024168A2 (pt) 2017-07-11
CN103501790A (zh) 2014-01-08
EP2688570B1 (en) 2015-11-18
KR102080151B1 (ko) 2020-02-21
CA2830515A1 (en) 2012-09-27
US20120245131A1 (en) 2012-09-27
JP6174563B2 (ja) 2017-08-02
EP2688570A2 (en) 2014-01-29
KR20140074253A (ko) 2014-06-17
MX354409B (es) 2018-03-05
AU2012230974B2 (en) 2016-05-12
SG193380A1 (en) 2013-10-30
CN106420767A (zh) 2017-02-22
WO2012129324A2 (en) 2012-09-27
ES2561536T3 (es) 2016-02-26
US20160279144A1 (en) 2016-09-29
MX2013010650A (es) 2013-10-07
WO2012129324A9 (en) 2012-11-15
US9364486B2 (en) 2016-06-14
DK2688570T3 (en) 2015-12-21
JP2014508807A (ja) 2014-04-10

Similar Documents

Publication Publication Date Title
CN116554168A (zh) Cxcr4抑制剂及其用途
CN103501790B (zh) 用于神经轴突的髓鞘再生的6-取代的雌二醇衍生物
Guo et al. Hypoxia-induced neuronal activity in glioma patients polarizes microglia by potentiating RNA m6A demethylation
Zhu et al. Exosomal microRNAs induce tumor-associated macrophages via PPARγ during tumor progression in SHH medulloblastoma
Mao et al. miR-17-92 facilitates neuronal differentiation of transplanted neural stem/precursor cells under neuroinflammatory conditions
JP5981434B2 (ja) 選択的ＥＲ−βアゴニストとしての６−置換デメチル−エストラジオール誘導体
Li et al. Long Non-Coding RNA MALAT1 Protects Against Spinal Cord Injury via Suppressing microRNA-125b-5p Mediated Microglial M1 Polarization, Neuroinflammation, and Neural Apoptosis
Qian et al. CircUBE3B high expression participates in sevoflurane-induced human hippocampal neuron injury via targeting miR-326 and regulating MYD88 expression
US20120094958A1 (en) Quinolines as inhibitors of farnesyl pyrophosphate synthase
AU2018201003A1 (en) 6-substituted estradiol derivatives for the treatment of alzheimer's disease
Zhang et al. M2 microglia-derived small extracellular vesicles modulate NSC fate after ischemic stroke via miR-25-3p/miR-93-5p-TGFBR/PTEN/FOXO3 axis
US20230097440A1 (en) Methods for modulation of lipoprotein lipase and apolipoprotein c2 expression and/or activity in the treatment of peripheral and central nervous system tissue disease states
CN114206869A (zh) Cxcr4抑制剂和其用途
Zhang et al. Nanotherapeutic Approaches of Interleukin-3 to Clear the 𝜶-Synuclein Pathology in Mouse Models of Parkinson’s
WO2023234740A1 (ko) Cd244 발현 또는 활성을 억제시킨 단핵구 또는 대식세포를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
Liu et al. Bone Marrow Mesenchymal Stem Cell-Derived Exosomal miR-126 Inhibits Colon Cancer by Targeting PLEXIN-B2

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160817